ICU dialysis: which dose of blood thinner works best?

NCT ID NCT07469072

Recruiting now Disease control Sponsor: Zhujiang Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares two starting doses (20 mg/h vs. 50 mg/h) of the blood thinner nafamostat in ICU patients receiving continuous kidney dialysis. The goal is to see which dose keeps the dialysis filter from clotting longer while avoiding dangerous bleeding. About 92 adults will be randomly assigned to one of the two doses, and doctors will track how long each filter lasts.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Nafamostat Mesilate (a blood-thinning drug)
What this could lead to: If it works, this could help doctors choose the best dose of nafamostat to keep dialysis filters working longer and reduce bleeding risks in ICU patients.
What could go wrong: This is a small, early-phase trial (92 people) at one hospital, so results may not apply to all patients. The drug can cause bleeding, and the higher dose may not be safer or more effective.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CONTINUOUS RENAL REPLACEMENT THERAPY (CRRT) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CONTINUOUS RENAL REPLACEMENT THERAPY (CRRT)

Contacts and locations

Locations

Department of Critical Care Medicine of Zhujiang Hospital,Southern Medical University
RECRUITING

Guangzhou, Guangdong, 510282, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.